Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Review, H1 2016', provides in depth analysis on Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2)
- The report reviews Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) Overview 9
Therapeutics Development 10
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Stage of Development 10
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Therapy Area 11
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Indication 12
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Companies 17
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Universities/Institutes 20
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Therapeutics Assessment 22
Assessment by Monotherapy/Combination Products 22
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Companies Involved in Therapeutics Development 27
Connexios Life Sciences Pvt. Ltd. 27
CymaBay Therapeutics, Inc. 28
Genfit SA 29
GlaxoSmithKline Plc 30
Inventiva 31
Mitobridge, Inc. 32
Nippon Chemiphar Co., Ltd. 33
Plexxikon Inc. 34
T3D Therapeutics, Inc. 35
vTv Therapeutics LLC 36
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Drug Profiles 37
CNX-013B2 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
elafibranor - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
GW-610742 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
HPP-593 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
IVA-337 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
MBX-8025 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
NC-2400 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Agonize Pan PPAR for Multiple Sclerosis - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecules to Inhibit PPAR Beta and PPAR Delta for Metabolic Disorders, Inflammatory Diseases and Oncology - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Target PPAR delta for Mitochondrial Diseases - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
T3D-959 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Dormant Projects 62
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Discontinued Products 65
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Featured News & Press Releases 66
Mar 31, 2016: GENFIT to Begin Elafibranor Clinical Program in PBC 66
Mar 30, 2016: Presentations at EASL/ILC 2016 Highlight Progress in NASH Treatment, Biomarker Diagnostics, and Programs Targeting Fibrotic Diseases 66
Mar 17, 2016: CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia 68
Mar 10, 2016: GENFIT announces enrollment of first patient in RESOLVE-IT, the pivotal Phase 3 clinical trial of Elafibranor in NASH 69
Feb 25, 2016: Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress 70
Feb 11, 2016: Data from phase 2b trial of Genfit elafibranor published in Gastroenterology 71
Jan 28, 2016: IVA337 delivers significant therapeutic advances in fibrosis, a major public health challenge 73
Nov 16, 2015: GENFIT Announces Pivotal Phase 3 Clinical Trial of Elafibranor in NASH Following Regulatory Input 74
Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis 76
Jun 22, 2015: T3D Therapeutics Receives FDA IND Approval to Begin Phase 2 Clinical Study of T3D-959 in Alzheimer's Patients 76
Jun 08, 2015: T3D Therapeutics Selected by the Alzheimer's Association to Present Pre-Clinical Results of T3D-959 at the 2015 Alzheimer's Association International Conference 77
Apr 24, 2015: New Proof Of Efficacy Of Gft505 In Nash And Positive Expert Opinion 77
Apr 23, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia 79
Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia 79
Mar 26, 2015: Genfit Announces Topline Results From The Golden-505 Trial In Nash 80
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 83
Disclaimer 8

List of Tables

Number of Products under Development for, H1 2016 10
Number of Products under Development by Therapy Area, H1 2016 11
Number of Products under Development by Indication, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Comparative Analysis by Unknown Stage Development, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Products under Investigation by Universities/Institutes, H1 2016 21
Assessment by Monotherapy/Combination Products, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 26
Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016 27
Pipeline by CymaBay Therapeutics, Inc., H1 2016 28
Pipeline by Genfit SA, H1 2016 29
Pipeline by GlaxoSmithKline Plc, H1 2016 30
Pipeline by Inventiva, H1 2016 31
Pipeline by Mitobridge, Inc., H1 2016 32
Pipeline by Nippon Chemiphar Co., Ltd., H1 2016 33
Pipeline by Plexxikon Inc., H1 2016 34
Pipeline by T3D Therapeutics, Inc., H1 2016 35
Pipeline by vTv Therapeutics LLC, H1 2016 36
Dormant Projects, H1 2016 62
Dormant Projects (Contd..1), H1 2016 63
Dormant Projects (Contd..2), H1 2016 64
Discontinued Products, H1 2016 65